Skip to content
Boost Up Blog – Lifestyle
Author:
C4 Therapeutics, Inc.
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
October 29, 2026
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
September 25, 2026
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
September 3, 2026
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 11, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2026
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
June 11, 2026
C4 Therapeutics to Participate in Upcoming Conferences
May 22, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 21, 2026
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 20, 2026